![Andrea Necchi: Results from the ECHO-307/KEYNOTE-672 study](https://oncodaily.com/pub/uploads/2024/06/download-53-1280x720.jpg)
Photo of Andrea Necchi from youtube.com
Jul 26, 2024, 19:39
Andrea Necchi: Results from the ECHO-307/KEYNOTE-672 study
Andrea Necchi, Associate Professor at Vita-Salute San Raffaele University, shared on X:
“IDO1 inhibition was ineffective in urothelial carcinoma.
Pembrolizumab and epacadostat/placebo for cis-ineligible urothelial carcinoma:
ECHO-307/KEYNOTE-672 study, BMC Cancer, also negatively tested in neoadjuvant setting.”
Source: Andrea Necchi/X
Authors: Andrea Necchi, Michiel S. Van der Heijden, Dmytro Trukhin, Avivit Peer, Howard Gurney, Boris Y. Alekseev, Francis X. Parnis, Raya Leibowitz, Maria De Santis, Petros Grivas, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Arjun V. Balar and Ronald de Wit.
Andrea Necchi
Arjun V. Balar
Avivit Peer
BMC Cancer
Boris Y. Alekseev
Calvin Jia
cancer
Dmytro Trukhin
ECHO-307/KEYNOTE-672 study
epacadostat
Francis X. Parnis
Howard Gurney
Jason Clark
Maria De Santis
Michiel S. Van der Heijden
Mihaela Munteanu
OncoDaily
Oncology
pembrolizumab
Petros Grivas
Raya Leibowitz
Ritesh Kataria
Ronald de Wit
urothelial carcinoma
Vita-Salute San Raffaele University